Cethromycin demonstrated a favorable safety profile in Trial CL-05. The incidence of adverse events was not statistically different between cethromycin and Biaxin.

Cethromycin was evaluated using a 300 mg once-daily dosing regimen compared to 250 mg twice-daily dosing for Biaxin, both over a seven-day course of therapy.

Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure ...

Advanced Life Sciences Holdings Inc. is proceeding with its new drug application (NDA) for cethromycin in community-acquired pneumonia (CAP) after results of the second of two pivotal clinical trials ...

Cethromycin, which is an oral antibiotic treating mild-to-moderate community acquired pneumonia (CAP), cured 94 percent of patients, compared to Biaxin, a current standard of care treatment for ...

The FDA sensitivity analyses that exposed cethromycin should have no impact on the Solithera registrational trials, which were large and well-run. In conclusion, the short-slanted piece was full ...

Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL07-001, a thorough QT study of the Company's novel once-a-day oral antibiotic, ...

Ketek and cethromycin are aimed at patients who get pneumonia outside of a hospital or extended-care facility. This community-acquired pneumonia, or CAP, is a common lung inflammation often caused ...

Advanced Life Sciences expects its 2009 cash requirements, excludingmilestone payments that become due upon cethromycin NDA approval, to fall inthe range of $12.0 million and $15.0 million. Cash ...

Advanced Life Sciences Holdings Announces Cethromycin Granted FDA Orphan Drug Designation for Anthrax WOODRIDGE, Ill., March 14, 2007 -- Advanced Life Sciences Holdings, Inc. today announced that ...

Advanced Life Sciences (NASDAQ:ADLS) reported positive data in an anthrax study last week for its potential antibiotic cethromycin. In March, cethromycin was granted an FDA Orphan Drug designation ...